Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05165407 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)

Study acronym: NESSIE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 14, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Mar 2024 to Sep 2025v2 Show 4 more changesShow less
    • Start date changed from estimate of Mar 2022 to Jul 12, 2022
    • Enrollment target: 40 to 30
    • Study completion date: Mar 2025 to Sep 2025
    • Study title expanded, about 1 word
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase II, single arm, open-label, multicenter study to evaluate the efficacy and safety of Sintilimab combined with IBI310 and Surufatinib for the treatment of high-grade advanced-neuroendocrine neoplasm
Trial Details
NCT Number NCT05165407
Lead Sponsor Peking University
Conditions
(from sponsor)		 Neuroendocrine Neoplasm
Related terms Neuroendocrine Tumors
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov